NCT05772611 Characterization of Immune-response in Autoimmune Encephalitis and Paraneoplastic Neurological Syndromes
| NCT ID | NCT05772611 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Autoimmune Encephalitis |
| Study Type | OBSERVATIONAL |
| Enrollment | 180 participants |
| Start Date | 2022-02-01 |
| Primary Completion | 2024-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 180 participants in total. It began in 2022-02-01 with a primary completion date of 2024-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare neuroimmune syndromes with a wide range of clinical presentation but without pathognomonic clinical sign facilitating the diagnosis. A lot of differential diagnoses are possible such as neurodegenerative diseases or viral infections. Although rare the diagnosis of AE or PNS is essential because despite severe neurological symptoms, patients can be cured by appropriate immunotherapy. Autoantibodies highly specific of AE and PNS has been described in the serum and cerebrospinal fluid of the patients and can be used as biomarkers of the disease. Their presence can predict an autoimmune origin and in many cases a good prognosis after immunotherapy. However, if some autoantibodies are now well-characterized and industrial kits have been developed to detect them, in numerous cases of highly suspect AE or PNS no specific autoantibodies are identified leading frequently to an inappropriate treatment. Furthermore, as the mechanisms of AE and PNS is still unknown, treatments are not optimal and in some cases inefficient. There is no prognosis biomarker able to predict the patient's sensitivity to immunotherapy and there are only few clues to know how the immune system can provoke the neuropsychiatric symptoms observed in the patients.
Eligibility Criteria
Inclusion Criteria: * Patient with neurological disorder * Patient with antibodies or not in sera or CSF Exclusion Criteria: \- No available clinical data
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05772611 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05772611 currently recruiting?
Yes, NCT05772611 is actively recruiting participants. Contact the research team at jerome.honnorat@chu-lyon.fr for enrollment information.
Where is the NCT05772611 trial being conducted?
This trial is being conducted at Lyon, France.
Who is sponsoring the NCT05772611 clinical trial?
NCT05772611 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 180 participants.